target="_blank" rel="nofollow" href="#ulink_2f5d54e1-8680-5f9a-8779-b7de2a769a96">Table 6.4 Quantity of cells in the PBSC components.5 Chapter 7Table 7.1 Tests of donor blood performed in the United States.Table 7.2 Automated systems for red cell typing and antibody testing of donat...Table 7.3 Common causes of ABO typing discrepancies.Table 7.4 Automated systems for infectious disease testing of donated blood.Table 7.5 Sequence of testing of donated blood.
6 Chapter 8Table 8.1 Major red blood cell group systems containing 230 antigen specifici...Table 8.2 Molecular and biochemical characteristics of the International Soci...Table 8.3 A1A2BO phenotype, gene, and genotype frequencies in southern Englan...Table 8.4 Genes and antigens of the ABH system and ABO type of donor red cell...Table 8.5 Serologic reactions and the Weiner and Fisher–Race nomenclature for...Table 8.6 General laboratory reactions of some blood group antibodies.Table 8.7 Methods of characterizing red cell antibodies.Table 8.8 Rare blood types associated with abnormal morphology or disease.Table 8.9 Clinical conditions with red cell antigen alteration.Table 8.10 Functions of molecules that contain red cell blood group antigens.Table 8.11 Human platelet allo‐antigens.Table 8.12 Clinical situations involving platelet‐specific antigens and antib...Table 8.13 Granulocyte alloantigens.Table 8.14 Clinical situations involving granulocyte‐specific antigens and an...
7 Chapter 9Table 9.1 Situations in which the direct antiglobulin test may be positive.Table 9.2 Key steps in compatibility testing.Table 9.3 Situations in which hemolysis can occur when the antibody screening...Table 9.4 Indications for repeat identification of red cell antibodies.Table 9.5 ABO antigens, antibodies, and donors suitable for transfusion to pa...Table 9.6 Strategy for providing blood.Table 9.7 Approximate time required to provide compatible red blood cells in ...Table 9.8 Steps in the evaluation of potential hemolytic disease of the fetus...
8 Chapter 10Table 10.1 Physiologic responses to anemia.Table 10.2 Aspects of bloodless medicine program.Table 10.3 Clinical situations involving leukocyte or platelet antibodies.Table 10.4 Clinical situations in which leukodepleted red cells are recommend...Table 10.5 Composition of fibrin sealant.Table 10.6 Indications for fibrin sealants.Table 10.7 Situations in which platelet transfusion may be necessary.Table 10.8 Platelet transfusion: a clinical practice guideline from the AABBTable 10.9 Patient‐related factors associated with reduced response to platel...Table 10.10 Practical strategies for dealing with a platelet refractory patie...Table 10.11 Quick reference of potent immunosuppressive medications (generic ...
9 Chapter 11Table 11.1 Reaction to acute blood loss of increasing severity.Table 11.2 Mechanisms to maintain oxygenation of the brain and heart during a...Table 11.3 Comparison of crystalloid and colloid solutions.Table 11.4 Factors to consider in changing blood types in acutely bleeding pa...Table 11.5 Definitions of massive transfusions.Table 11.6 Potential transfusion complications.Table 11.7 Changes in RBC units during storage [9].Table 11.8 Potential consequences of rapid red blood cell transfusion.Table 11.9 Definition of parameters.Table 11.10 Blood component utilization by patients undergoing bone marrow tr...Table 11.11 Theoretical immunohematologic consequences of ABO‐incompatible bo...Table 11.12 Potential complications of exchange transfusion.Table 11.13 General indications for transfusion in sickle cell anemia.Table 11.14 Autoimmune hemolytic anemia.
10 Chapter 12Table 12.1 Key elements of a patient blood management program?Table 12.2 Blood management considerations for cardiovascular surgery patient...Table 12.3 Autologous blood collection techniques in selected surgical proced...Table 12.4 Cardiovascular conditions proposed as contraindications to autolog...Table 12.5 Complications unique to autologous transfusion.Table 12.6 Theoretical advantages of acute normovolemic hemodilution.Table 12.7 Criteria for acute normovolemic hemodilution.Table 12.8 Intraoperative salvage devices.
11 Chapter 13Table 13.1 Guidelines for transfusion of red blood cells in patients <4 month...Table 13.2 Potential complications of exchange transfusion.Table 13.3 Red blood cell requirements for intrauterine transfusion.Table 13.4 Steps in the evaluation of potential hemolytic disease of the newb...
12 Chapter 14Table 14.1 Ideal features of a pathogen technology.Table 14.2 Pathogen reduction for different blood products.Table 14.3 The reasons for failure for a virus to transmit infection.Table 14.4 Characteristics of viruses that affect infectivity.Table 14.5 Randomized controlled clinical trials of pathogen reduced platelet...
13 Chapter 15Table 15.1 Acceptable blood component storage and transport temperatures.Table 15.2 Premedications to prevent potential transfusion reactions.
14 Chapter 16Table 16.1 Complications of transfusion.Table 16.2 Adverse effects of leukocytes in blood components.Table 16.3 Transfusion‐related fatalities by complication, FY2013 through FY2...Table 16.4 Causes of red cell hemolysis associated with red cell transfusions...Table 16.5 Laboratory test abnormalities in patients experiencing a hemolytic...Table 16.6 Recommended criteria for TRALI and possible TRALI.Table 16.7 Strategies to prevent transfusion‐associated sepsis for all blood ...Table 16.8 US Food and Drug Administration guidance to further prevent transf...Table 16.9 Signs and symptoms of a hemolytic transfusion reaction.Table 16.10 Symptoms related to different transfusion reactions.Table 16.11 Steps to take when a transfusion reaction occurs.Table 16.12 Kinds of clinical problems caused by immunization after blood tra...Table 16.13 Clinical and pathologic comparison of graft‐versus‐host disease a...Table 16.14 Transfusion‐associated circulatory overload criteria.
15 Chapter 17Table 17.1 General strategies to reduce disease transmission.Table 17.2 Blood bank procedures to reduce the infectivity of the blood suppl...Table 17.3 Estimates of transfusion‐transmitted disease in the United States.Table 17.4 Factors that could influence the infectivity of a transfusion.Table 17.5 Other transfusion‐transmitted diseases of interest.Table 17.6 Issues in considering new transfusion‐transmissible disease screen...
16 Chapter 18Table 18.1 Numbers of recognized private HLA antigen specificities and allele...
17 Chapter 19Table 19.1 Clinical uses of engineered cells.Table 19.2 Types of hematopoietic stem and progenitor cells used as source ma...Table 19.3 Approximate composition of hematopoietic stem cell products after ...Table 19.4 Issues to be considered in developing cord blood banks.
18 Chapter 20Table 20.1 Types of therapeutic apheresis procedures.Table 20.2 Type of disease in which therapeutic plasma exchange may be used.Table 20.3 Type of material being removed by plasma exchange.Table 20.4 Indication categories for therapeutic apheresis.Table 20.5 American Society for Apheresis 2019 indications category and grade...Table 20.6 Therapeutic apheresis devices available in the United States.Table 20.7 Comparison of changes induced by plasma exchange of 1.0–1.5 plasma...Table 20.8 Complications of plasma exchange.Table 20.9 Therapeutic applications of photopheresis.
19 Chapter 21Table 21.1 Differences between blood component production and pharmaceutical ...Table 21.2 Process analysis and management.Table 21.3 Quality principles according to the AABB.Table 21.4 Good Manufacturing Practices.Table 21.5 International Organization for Standardization 9000 quality system...Table 21.6 The quality hierarchy.Table 21.7 Activities of a hospital blood bank that are subject to quality pr...Table 21.8 Activities in the transfusion of blood and components that are par...Table 21.9 Quality in transfusion therapy.
List of Illustrations
1 Chapter 2Figure 2.1 US allogeneic white blood/red blood cell collections and transfus...Figure 2.2 Red blood cell use by hospital service in 2013. BMT, bone marrow ...
2 Chapter 5Figure 5.1 Diagram showing unit of whole blood and integral plastic bag syst...Figure
